Core Viewpoint - Metallus Inc. is under investigation for potential securities fraud and unlawful business practices following disappointing financial results for Q1 2025, which led to a significant drop in its stock price [1][3]. Financial Performance - Metallus reported non-GAAP earnings per share of $0.07 for Q1 2025, missing consensus estimates by $0.05 [3]. - The company's stock price fell by $1.48, or 11.31%, closing at $11.61 per share on May 9, 2025, following the earnings announcement [3]. Management Commentary - The CEO of Metallus indicated that the company experienced volatility in the defense supply chain during the first quarter, attributed to customer manufacturing start-up challenges [3].

Core Viewpoint - Northrop Grumman Corporation is under investigation for potential securities fraud and unlawful business practices following disappointing financial results for Q1 2025, which included significant charges related to its B-21 bomber program [1][3]. Financial Performance - Northrop Grumman reported revenue of $9.47 billion for Q1 2025, reflecting a 7% year-over-year decline and falling short of consensus estimates by $480 million [3]. - The company incurred a pretax charge of $477 million associated with manufacturing updates for the B-21 bomber program, attributed to inflationary factors by the CEO [3]. - Following the announcement of these results, Northrop Grumman's stock price dropped by $67.25 per share, or 12.66%, closing at $464.08 per share on April 22, 2025 [3]. Legal Investigation - Pomerantz LLP is investigating claims on behalf of investors regarding potential securities fraud or other unlawful practices by Northrop Grumman and its officers/directors [1].

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud and unlawful business practices involving Bausch + Lomb Corporation and its executives [1] Group 1: Product Recall and Stock Impact - On March 27, 2025, Bausch + Lomb announced a voluntary recall of intraocular lenses due to reports of toxic anterior segment syndrome, leading to a stock price drop of $1.54 per share, or 9.83%, closing at $14.13 on March 28, 2025 [3] - Following the recall, on April 30, 2025, Bausch + Lomb reported an adjusted net loss of $54 million for Q1 2025, a significant decline from an adjusted net income of $24 million in Q1 2024 [4] - The company revised its full-year growth outlook down to 4.5% to 6.5%, from a previous estimate of 5.5% to 7.5%, citing the impact of the enVista product recall [4] - On the same day, the stock price fell by $2.16 per share, or 15.74%, closing at $11.56 [5] Group 2: Legal Investigation - Pomerantz LLP, a prominent firm in corporate and securities class litigation, is leading the investigation into Bausch + Lomb's practices, emphasizing its long history of fighting for victims of securities fraud [6]

NEW YORK, May 13, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of GoHealth, Inc. (“GoHealth” or the “Company”) (NASDAQ: GOCO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether GoHealth and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the class action] On May 1, 2025, th ...

Core Viewpoint - Pomerantz LLP is investigating claims of potential securities fraud and unlawful business practices involving SelectQuote, Inc. following a lawsuit filed by the U.S. Department of Justice against the company and others in the health insurance sector [1][3]. Group 1: Investigation Details - Pomerantz LLP is representing investors of SelectQuote and is looking into whether the company and its officers engaged in illegal activities [1]. - The investigation is prompted by allegations that SelectQuote participated in a scheme involving illegal kickbacks related to Medicare Advantage plan enrollments [3]. Group 2: Legal Context - On May 1, 2025, the DOJ filed a False Claims Act complaint against SelectQuote and other insurers, claiming they paid hundreds of millions in illegal kickbacks from 2016 to 2021 [3]. - Following the announcement of the DOJ's lawsuit, SelectQuote's stock price dropped by $0.61, or 19.24%, closing at $2.56 per share [3]. Group 3: Firm Background - Pomerantz LLP is recognized as a leading firm in corporate, securities, and antitrust class litigation, with a history of fighting for victims of securities fraud and corporate misconduct [4].

Core Viewpoint - Pomerantz LLP is investigating claims of potential securities fraud and unlawful business practices involving Humana Inc. and its officers or directors [1] Group 1: Legal Issues - The U.S. Department of Justice filed a False Claims Act complaint against Humana and other health insurance companies, alleging that from 2016 to at least 2021, they paid hundreds of millions of dollars in illegal kickbacks to brokers for enrollments in Medicare Advantage plans [3] - Following the DOJ's lawsuit announcement, Humana's stock price decreased by $6.20 per share, or 2.36%, closing at $256.04 on May 1, 2025 [3] Group 2: Company Background - Pomerantz LLP is recognized as a leading firm in corporate, securities, and antitrust class litigation, with a history of recovering multimillion-dollar damages for victims of securities fraud and corporate misconduct [4]

NEW YORK, May 13, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against The Bancorp, Inc. (NASDAQ: TBBK) and certain of the Company's senior executives for potential violations of the federal securities laws. If you invested in Bancorp, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/the-bancorp-inc. What Can You Do? Investors have until May 16, 2025, to ask the Court to be a ...

Core Viewpoint - Cable One, Inc. is under investigation for potential securities fraud and unlawful business practices following disappointing financial results and a significant stock price drop [1][2]. Financial Performance - On May 1, 2025, Cable One reported Q1 2025 earnings that fell significantly short of analyst expectations and announced the suspension of its dividend [2]. - Analysts from Keybanc described the results as "extremely disappointing," while Raymond James criticized management's optimism regarding future growth in broadband revenue and subscribers despite poor Q1 performance [2]. Stock Market Reaction - Following the release of the disappointing financial results, Cable One's stock price plummeted by $109.48 per share, or 41.79%, closing at $152.51 per share on May 2, 2025 [2].

NEW YORK, May 12, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  Cleveland-Cliffs Inc. ("Cleveland-Cliffs" or the "Company") (NYSE: CLF). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.The investigation concerns whether Cleveland-Cliffs and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the class action]On May ...

Core Viewpoint - A class action lawsuit has been filed against Bitfarms Ltd. and certain officers for alleged violations of federal securities laws during the Class Period from March 21, 2023, to December 9, 2024, seeking damages for misleading statements regarding the company's financial reporting and internal controls [1][6][8]. Company Overview - Bitfarms operates integrated Bitcoin data centers in Canada, the U.S., Paraguay, and Argentina, focusing on mining Bitcoin and managing digital assets [3]. - The company sells mined Bitcoin and accounts for the proceeds in its cash flow statement, which includes cash flow from operating, investing, and financing activities [4]. Financial Reporting Issues - In March 2024, Bitfarms identified a material weakness in its internal control over financial reporting related to the classification of 2021 Warrants, which should have been classified as financial liabilities rather than equity instruments [6]. - The company acknowledged that its internal controls were deficient, leading to misstatements in financial statements and the need for restatements [7][8]. Recent Developments - On December 9, 2024, Bitfarms announced that its consolidated financial statements for 2022 and 2023 contained a material error regarding the classification of proceeds from digital asset sales, which would need to be restated [8]. - Following this announcement, Bitfarms' stock price fell by $0.13 per share, or 6.07%, closing at $2.01 per share on December 10, 2024 [8]. - In its Annual Report on Form 40-F filed on April 1, 2025, Bitfarms reiterated its efforts to remediate the material weakness but indicated that the remediation plan would be completed in 2025, contrary to previous statements [9].